PMC:7335494 / 56393-57268 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T411","span":{"begin":411,"end":424},"obj":"Body_part"},{"id":"T412","span":{"begin":564,"end":582},"obj":"Body_part"},{"id":"T413","span":{"begin":606,"end":611},"obj":"Body_part"},{"id":"T414","span":{"begin":721,"end":725},"obj":"Body_part"},{"id":"T415","span":{"begin":726,"end":739},"obj":"Body_part"},{"id":"T416","span":{"begin":744,"end":750},"obj":"Body_part"}],"attributes":[{"id":"A411","pred":"fma_id","subj":"T411","obj":"http://purl.org/sig/ont/fma/fma82779"},{"id":"A412","pred":"fma_id","subj":"T412","obj":"http://purl.org/sig/ont/fma/fma82785"},{"id":"A413","pred":"fma_id","subj":"T413","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A414","pred":"fma_id","subj":"T414","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A415","pred":"fma_id","subj":"T415","obj":"http://purl.org/sig/ont/fma/fma82779"},{"id":"A416","pred":"fma_id","subj":"T416","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"These n-3 PUFAs frequently substitute n-6 PUFAs like ARA, resulting in decreased availability of ARA for eicosanoid synthesis. EPA also inhibits ARA metabolism as a competitive substrate for COX-2, decreasing prostaglandin E2 (PGE2) production. In rats, dietary supplementation with ALA inhibits PG biosynthesis from ARA, while equivalent quantities of ALA and LA decreased up to 40% n-6 PUFAs incorporation in phospholipids (Calder, 2017). Furthermore, Rees et al. observed that a daily EPA intake of 2.7 g or 4.05 g for 3 months decreases the PGE2 production by lipopolysaccharide-stimulated mononuclear cells, while a lower dose of 1.35 g did not. EPA was integrated in a linear dose-dependent manner into mononuclear cell phospholipids and plasma. This study suggested a daily threshold in the range of 1.35–2.7 g EPA for the anti-inflammatory action (Rees et al., 2006)."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T613","span":{"begin":163,"end":164},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T614","span":{"begin":223,"end":225},"obj":"http://purl.obolibrary.org/obo/CLO_0002860"},{"id":"T615","span":{"begin":296,"end":298},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T616","span":{"begin":480,"end":481},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T617","span":{"begin":594,"end":611},"obj":"http://purl.obolibrary.org/obo/CL_0000842"},{"id":"T618","span":{"begin":619,"end":620},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T619","span":{"begin":673,"end":674},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T620","span":{"begin":709,"end":725},"obj":"http://purl.obolibrary.org/obo/CL_0000842"},{"id":"T621","span":{"begin":744,"end":750},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T622","span":{"begin":773,"end":774},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"These n-3 PUFAs frequently substitute n-6 PUFAs like ARA, resulting in decreased availability of ARA for eicosanoid synthesis. EPA also inhibits ARA metabolism as a competitive substrate for COX-2, decreasing prostaglandin E2 (PGE2) production. In rats, dietary supplementation with ALA inhibits PG biosynthesis from ARA, while equivalent quantities of ALA and LA decreased up to 40% n-6 PUFAs incorporation in phospholipids (Calder, 2017). Furthermore, Rees et al. observed that a daily EPA intake of 2.7 g or 4.05 g for 3 months decreases the PGE2 production by lipopolysaccharide-stimulated mononuclear cells, while a lower dose of 1.35 g did not. EPA was integrated in a linear dose-dependent manner into mononuclear cell phospholipids and plasma. This study suggested a daily threshold in the range of 1.35–2.7 g EPA for the anti-inflammatory action (Rees et al., 2006)."}

LitCovid-PD-CHEBI

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T194","span":{"begin":116,"end":125},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T195","span":{"begin":149,"end":159},"obj":"http://purl.obolibrary.org/obo/GO_0008152"},{"id":"T196","span":{"begin":299,"end":311},"obj":"http://purl.obolibrary.org/obo/GO_0009058"}],"text":"These n-3 PUFAs frequently substitute n-6 PUFAs like ARA, resulting in decreased availability of ARA for eicosanoid synthesis. EPA also inhibits ARA metabolism as a competitive substrate for COX-2, decreasing prostaglandin E2 (PGE2) production. In rats, dietary supplementation with ALA inhibits PG biosynthesis from ARA, while equivalent quantities of ALA and LA decreased up to 40% n-6 PUFAs incorporation in phospholipids (Calder, 2017). Furthermore, Rees et al. observed that a daily EPA intake of 2.7 g or 4.05 g for 3 months decreases the PGE2 production by lipopolysaccharide-stimulated mononuclear cells, while a lower dose of 1.35 g did not. EPA was integrated in a linear dose-dependent manner into mononuclear cell phospholipids and plasma. This study suggested a daily threshold in the range of 1.35–2.7 g EPA for the anti-inflammatory action (Rees et al., 2006)."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T317","span":{"begin":0,"end":126},"obj":"Sentence"},{"id":"T318","span":{"begin":127,"end":244},"obj":"Sentence"},{"id":"T319","span":{"begin":245,"end":440},"obj":"Sentence"},{"id":"T320","span":{"begin":441,"end":650},"obj":"Sentence"},{"id":"T321","span":{"begin":651,"end":751},"obj":"Sentence"},{"id":"T322","span":{"begin":752,"end":875},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These n-3 PUFAs frequently substitute n-6 PUFAs like ARA, resulting in decreased availability of ARA for eicosanoid synthesis. EPA also inhibits ARA metabolism as a competitive substrate for COX-2, decreasing prostaglandin E2 (PGE2) production. In rats, dietary supplementation with ALA inhibits PG biosynthesis from ARA, while equivalent quantities of ALA and LA decreased up to 40% n-6 PUFAs incorporation in phospholipids (Calder, 2017). Furthermore, Rees et al. observed that a daily EPA intake of 2.7 g or 4.05 g for 3 months decreases the PGE2 production by lipopolysaccharide-stimulated mononuclear cells, while a lower dose of 1.35 g did not. EPA was integrated in a linear dose-dependent manner into mononuclear cell phospholipids and plasma. This study suggested a daily threshold in the range of 1.35–2.7 g EPA for the anti-inflammatory action (Rees et al., 2006)."}

MyTest

{"project":"MyTest","denotations":[{"id":"32640331-28900017-30720918","span":{"begin":434,"end":438},"obj":"28900017"},{"id":"32640331-16469992-30720919","span":{"begin":869,"end":873},"obj":"16469992"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"These n-3 PUFAs frequently substitute n-6 PUFAs like ARA, resulting in decreased availability of ARA for eicosanoid synthesis. EPA also inhibits ARA metabolism as a competitive substrate for COX-2, decreasing prostaglandin E2 (PGE2) production. In rats, dietary supplementation with ALA inhibits PG biosynthesis from ARA, while equivalent quantities of ALA and LA decreased up to 40% n-6 PUFAs incorporation in phospholipids (Calder, 2017). Furthermore, Rees et al. observed that a daily EPA intake of 2.7 g or 4.05 g for 3 months decreases the PGE2 production by lipopolysaccharide-stimulated mononuclear cells, while a lower dose of 1.35 g did not. EPA was integrated in a linear dose-dependent manner into mononuclear cell phospholipids and plasma. This study suggested a daily threshold in the range of 1.35–2.7 g EPA for the anti-inflammatory action (Rees et al., 2006)."}

2_test

{"project":"2_test","denotations":[{"id":"32640331-28900017-30720918","span":{"begin":434,"end":438},"obj":"28900017"},{"id":"32640331-16469992-30720919","span":{"begin":869,"end":873},"obj":"16469992"}],"text":"These n-3 PUFAs frequently substitute n-6 PUFAs like ARA, resulting in decreased availability of ARA for eicosanoid synthesis. EPA also inhibits ARA metabolism as a competitive substrate for COX-2, decreasing prostaglandin E2 (PGE2) production. In rats, dietary supplementation with ALA inhibits PG biosynthesis from ARA, while equivalent quantities of ALA and LA decreased up to 40% n-6 PUFAs incorporation in phospholipids (Calder, 2017). Furthermore, Rees et al. observed that a daily EPA intake of 2.7 g or 4.05 g for 3 months decreases the PGE2 production by lipopolysaccharide-stimulated mononuclear cells, while a lower dose of 1.35 g did not. EPA was integrated in a linear dose-dependent manner into mononuclear cell phospholipids and plasma. This study suggested a daily threshold in the range of 1.35–2.7 g EPA for the anti-inflammatory action (Rees et al., 2006)."}